山东大学耳鼻喉眼学报 ›› 2022, Vol. 36 ›› Issue (2): 32-39.doi: 10.6040/j.issn.1673-3770.0.2021.119
刘勇1,袁存立1,曹慧1,郑成彩1,晁方2, 许风雷3
LIU Yong1, YUAN Cunli1, CAO Hui1, ZHENG Chengcai1, CHAO Fang2, XU Fenglei3
摘要: 目的 探讨染色质解旋酶DNA结合蛋白(CHD1L)在喉鳞状细胞癌(LSCC)增殖、侵袭和转移中的作用机制,为喉鳞状细胞癌的治疗提供分子靶点。 方法 免疫组织化学方法检测60例喉鳞状细胞癌组织和其配对癌旁正常黏膜组织中CHD1L、上皮性钙黏着蛋白(E-cadherin)和波形蛋白(Vimentin)的表达;Western blotting法检测人支气管上皮细胞(HBE)和人喉表皮样癌细胞(HEp-2)中CHD1L表达。敲除HEp-2细胞中的CHD1L,并用Western blotting法检测HEp-2细胞内CHD1L、E-cadherin和Vimentin的表达;CCK-8实验检测各组细胞增殖情况,Transwell侵袭实验检测各组细胞的侵袭情况。 结果 免疫组化结果显示CHD1L在喉鳞状细胞癌组织中的阳性表达率明显高于癌旁正常黏膜组织中的阳性表达率,且其阳性表达与喉鳞状细胞癌的分化程度、淋巴结转移、临床分期及Vimentin的表达呈正相关,而与E-cadherin的表达呈负相关(P<0.05)。Western blotting结果显示CHD1L在HEp-2细胞中的表达明显高于HBE细胞。用干扰质粒体外敲减HEp-2细胞中的CHD1L。体外敲减CHD1L的表达水平之后,HEp-2细胞的增殖能力及侵袭能力明显降低,E-cadherin的表达明显升高,Vimentin的表达明显降低。 结论 喉鳞状细胞癌组织中CHD1L呈高表达,与喉鳞状细胞癌细胞分化程度、临床分期及淋巴结转移密切相关,提示CHD1L在喉鳞状细胞癌中起着癌基因的作用;CHD1L可以通过促进喉鳞状细胞癌细胞的EMT进而促进喉鳞状细胞癌细胞的增殖、侵袭和转移。
中图分类号:
[1] Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018[J]. CA Cancer J Clin, 2018, 68(1): 7-30. doi:10.3322/caac.21442. [2] Tang X, Sun Y, Wan G, et al. Knockdown of YAP inhibits growth in Hep-2 laryngeal cancer cells via epithelial-mesenchymal transition and the Wnt/β-catenin pathway[J]. BMC Cancer, 2019, 19(1): 654.doi:10.1186/s12885-019-5832-9. [3] 蒋宏,王斌全,高泽慧,等.喉癌患者情绪和认知功能改变的研究进展[J].临床耳鼻咽喉头颈外科杂志,2018,32(11):880-882. doi:10.13201/j.issn.1001-1781.2018.11.021. JIANG Hong, WANG Binquan, GAO Zehui, et al. Research progress on the changes of emotional and cognitive functions in patients with laryngeal cancer[J]. Journal of Clinical Otorhinolaryngology Head and Neck Surgery, 2018, 32(11): 880-882. doi:10.13201/j.issn.1001-1781.2018.11.021. [4] Liu ZH, Zhang Q, Ding YJ, et al. Overexpression of CHD1L is associated with poor survival and aggressive tumor biology in esophageal carcinoma[J]. Oncotarget, 2017, 8(43): 74178-74187.doi:10.18632/oncotarget.18830. [5] Li SM, Chai Y, Ding YB, et al. CHD1L is associated with poor survival and promotes the proliferation and metastasis of intrahepatic cholangiocarcinoma[J]. Oncol Rep, 2019, 42(2): 657-669.doi:10.3892/or.2019.7174. [6] Mu QJ, Li HL, Yao Y, et al. Chromodomain helicase/ATPase DNA-binding protein 1-like gene(CHD1L)expression and implications for invasion and metastasis of breast cancer[J]. PLoS One, 2015, 10(11): e0143030. doi:10.1371/journal.pone.0143030. [7] Nieto MA, Huang RYJ, Jackson RA, et al. Emt: 2016[J]. Cell, 2016, 166(1): 21-45. doi:10.1016/j.cell.2016.06.028. [8] Su Z, Zhao J, Xian G, et al. CHD1L is a novel independent prognostic factor for gastric cancer[J]. Clin Transl Oncol, 2014, 16(8): 702-707. doi:10.1007/s12094-013-1136-8. [9] Famokunwa B, Walsted ES, Hull JH. Assessing laryngeal function and hypersensitivity[J]. Pulm Pharmacol Ther, 2019, 56: 108-115. doi:10.1016/j.pupt.2019.04.003. [10] Al-Rohil RN, Tarasen AJ, Carlson JA, et al. Evaluation of 122 advanced-stage cutaneous squamous cell carcinomas by comprehensive genomic profiling opens the door for new routes to targeted therapies[J]. Cancer, 2016, 122(2): 249-257. doi:10.1002/cncr.29738. [11] Peyvandi H, Peyvandi AA, Safaei A, et al. Introducing potential key proteins and pathways in human laryngeal cancer: a system biology approach[J]. Iran J Pharm Res, 2018, 17(1): 415-425. [12] Liu W, Xu J, Zhang C. Prognostic role of chromodomain helicase DNA binding protein 1-like protein in human solid cancers: a meta-analysis[J]. Medicine(Baltimore), 2018, 97(29): e11522.doi:10.1097/md.0000000000011522. [13] Li Y, He LR, Gao Y, et al. CHD1L contributes to cisplatin resistance by upregulating the ABCB1-NF-κB axis in human non-small-cell lung cancer[J]. Cell Death Dis, 2019, 10(2): 99. doi:10.1038/s41419-019-1371-1. [14] Su FR, Ding JH, Bo L, et al. Chromodomain helicase/ATPase DNA binding protein 1-like protein expression predicts poor prognosis in nasopharyngeal carcinoma[J]. Exp Ther Med, 2014, 8(6): 1745-1750. doi:10.3892/etm.2014.2017. [15] Tian F, Xu F, Zhang ZY, et al. Expression of CHD1L in bladder cancer and its influence on prognosis and survival[J]. Tumour Biol, 2013, 34(6): 3687-3690. doi:10.1007/s13277-013-0951-4. [16] Wang W, Wu J, Fei X, et al. CHD1L promotes cell cycle progression and cell motility by up-regulating MDM2 in breast cancer[J]. Am J Transl Res, 2019,11(3):1581-1592. [17] He LR, Ma NF, Chen JW, et al. Overexpression of CHD1L is positively associated with metastasis of lung adenocarcinoma and predicts patients poor survival[J]. Oncotarget, 2015, 6(31): 31181-31190.doi:10.18632/oncotarget.5070. [18] Skrypek N, Goossens S, De Smedt E, et al. Epithelial-to-mesenchymal transition: epigenetic reprogramming driving cellular plasticity[J]. Trends Genet, 2017, 33(12): 943-959.doi:10.1016/j.tig.2017.08.004. [19] Nakagawa H, Hikiba Y, Hirata Y, et al. Loss of liver E-cadherin induces sclerosing cholangitis and promotes carcinogenesis[J]. PNAS, 2014, 111(3): 1090-1095. doi:10.1073/pnas.1322731111. [20] Po JW, Roohullah A, Lynch D, et al. Improved ovarian cancer EMT-CTC isolation by immunomagnetic targeting of epithelial EpCAM and mesenchymal N-cadherin[J]. J Circ Biomark, 2018, 7: 184945441878261. doi:10.1177/1849454418782617. [21] Li T, Xie J, Shen C, et al. Upregulation of long noncoding RNA ZEB1-AS1 promotes tumor metastasis and predicts poor prognosis in hepatocellular carcinoma[J]. Oncogene, 2016, 35(12): 1575-1584.doi:10.1038/onc.2015.223. [22] Matysiak M, Kapka-Skrzypczak L, Jodowska-Jędrych B, et al. EMT promoting transcription factors as prognostic markers in human breast cancer[J]. Arch Gynecol Obstet, 2017, 295(4): 817-825.doi:10.1007/s00404-017-4304-1. [23] Mizukoshi K, Okazawa Y, Haeno H, et al. Metastatic seeding of human colon cancer cell clusters expressing the hybrid epithelial/mesenchymal state[J]. Int J Cancer, 2020, 146(9): 2547-2562.doi:10.1002/ijc.32672. [24] Karlsson MC, Gonzalez SF, Welin J, et al. Epithelial-mesenchymal transition in cancer metastasis through the lymphatic system[J]. Mol Oncol, 2017, 11(7): 781-791. doi:10.1002/1878-0261.12092. [25] Karamagkiolas S, Giotakis I, Kyrodimos E, et al. Expression of vimentin(VIM)and metastasis-associated 1(MTA1)protein in laryngeal squamous cell carcinoma are associated with prognostic outcome of patients[J]. Am J Otolaryngol, 2019, 40(4): 487-493. doi:10.1016/j.amjoto.2019.04.002. [26] Mezi S, Chiappetta C, Carletti R, et al. Clinical significance of epithelial-to-mesenchymal transition in laryngeal carcinoma: Its role in the different subsites[J]. Head Neck, 2017, 39(9): 1806-1818.doi:10.1002/hed.24838. [27] Haga RB, Ridley AJ. Rho GTPases: Regulation and roles in cancer cell biology[J]. Small GTPases, 2016, 7(4): 207-221. doi:10.1080/21541248.2016.1232583. [28] Liu M, Chen LL, Ma NF, et al. CHD1L promotes lineage reversion of hepatocellular carcinoma through opening chromatin for key developmental transcription factors[J]. Hepatology, 2016, 63(5): 1544-1559. doi:10.1002/hep.28437. [29] Li FF, Zhang Z, Wang P, et al. ALC1 knockdown enhances cisplatin cytotoxicity of esophageal squamous cell carcinoma cells by inhibition of glycolysis through PI3K/Akt pathway[J]. Life Sci, 2019,232: 116679. doi:10.1016/j.lfs.2019.116679. |
[1] | 陈东彦,钱晔,魏东敏,李文明,夏同良,雷大鹏,潘新良. 高频超声诊断下咽鳞癌淋巴结转移的临床研究[J]. 山东大学耳鼻喉眼学报, 2022, 36(5): 18-23. |
[2] | 颜繁诚,蒋现,柴一杰,王昊森,孟照洋,汪晓磊,王艳玲,冯雪. miR-30-5p通过下调FOXG1表达抑制视网膜母细胞瘤细胞增殖[J]. 山东大学耳鼻喉眼学报, 2022, 36(5): 63-69. |
[3] | 姜超,周炫辰,韩杰,岳志勇. IVc期下咽癌特征分析及列线图预后模型构建[J]. 山东大学耳鼻喉眼学报, 2022, 36(4): 49-54. |
[4] | 王俊鑫孙岩. miRNA-29b参与上皮间质转化相关信号通路调控的研究进展[J]. 山东大学耳鼻喉眼学报, 2021, 35(6): 132-137. |
[5] | 夏彩风,谢瑞玲,甄甄,文锋,王全桂. 鼻腔鼻窦转移性肾透明细胞癌一例报道并文献综述[J]. 山东大学耳鼻喉眼学报, 2021, 35(5): 36-45. |
[6] | 刘盼,王川,赵泽祺,吴梅,徐继峰,李巍,张伟强,刘稳. 头颈部转移性透明细胞癌5例并文献复习[J]. 山东大学耳鼻喉眼学报, 2021, 35(4): 45-50. |
[7] | 李静静, 武欣欣, 毛宁, 郑桂彬, 牟亚魁, 初同朋, 贾传亮, 郑海涛, 米佳, 宋西成. 基于CT影像组学诺模图术前预测甲状腺乳头状癌颈部中央区淋巴结转移的研究[J]. 山东大学耳鼻喉眼学报, 2021, 35(4): 51-59. |
[8] | 王莹莹,周涵,董伟达,邢光前,陈智斌,张清照,张立庆. 外耳道腺样囊性癌的远处转移及预后分析[J]. 山东大学耳鼻喉眼学报, 2021, 35(1): 1-6. |
[9] | 刘志高,王淑雅,韩旭光,王玉,李志伟,马爱华,赵博军. 增殖性糖尿病视网膜病变术前玻璃体腔应用阿柏西普的时机及其疗效观察[J]. 山东大学耳鼻喉眼学报, 2021, 35(1): 99-103. |
[10] | 庞振文,黄愉峰,杨爱芳,曾先捷. 喉癌患者术前中性粒细胞/淋巴细胞比值与淋巴结转移的相关性研究[J]. 山东大学耳鼻喉眼学报, 2020, 34(6): 58-62. |
[11] | 范义燕,张肖林,刘秀珍,尹晶晶,袁进,王延飞,陈军. CPS1在喉鳞癌组织中的表达及临床意义[J]. 山东大学耳鼻喉眼学报, 2020, 34(6): 72-76. |
[12] | 裴雪艳王琰. 侵袭性伪足和MMP-14在肿瘤发病机制中的研究进展[J]. 山东大学耳鼻喉眼学报, 2020, 34(6): 129-134. |
[13] | 青晓艳, 徐义全李超. 甲状腺未分化癌的分子机制研究[J]. 山东大学耳鼻喉眼学报, 2020, 34(3): 26-31. |
[14] | 陈海兵, 卫亚楠, 许晓泉, 陈曦. 基于XGBoost人工智能结合CT构建甲状腺癌颈部淋巴结转移预测模型[J]. 山东大学耳鼻喉眼学报, 2020, 34(3): 40-45. |
[15] | 吕静荣,陈淳,马衍,谢晋. 儿童分化型甲状腺癌的临床特征及危险因素分析[J]. 山东大学耳鼻喉眼学报, 2020, 34(3): 88-94. |
|